Klin Farmakol Farm. 2019;33(2):44-48 | DOI: 10.36290/far.2019.014

NexoBridTM: a novel agent for enzymatic necrolysis in a patient with thermal injury

Břetislav Lipový1,2, Jakub Holoubek1,2, Nikola Ševčíková1, Filip Raška1, Ivan Suchánek1
1 Klinika popálenin a rekonstrukční chirurgie FN Brno
2 Lékařská fakulta, Masarykova univerzita Brno

Removal of necrotic tissue in patients with deep burns is one of the fundamental steps that facilitate the subsequent multi-phased
process in wound healing. Persisting necrotic tissue in the wound bed represents an excellent growth medium for a number of
potentially pathogenic microorganisms. Currently, there are several ways of removing this necrosis. The case report presents the
latest method whose mechanism of action is enzymatic necrolysis, wherein selective dissolution of necrosis with preservation
of viable underlying tissue occurs.

Keywords: burns, enzymatic necrolysis, NexoBridTM

Published: July 10, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lipový B, Holoubek J, Ševčíková N, Raška F, Suchánek I. NexoBridTM: a novel agent for enzymatic necrolysis in a patient with thermal injury. Klin Farmakol Farm. 2019;33(2):44-48. doi: 10.36290/far.2019.014.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Janzekovic Z. A new concept in the early excision and immediate grafting of burns. J Trauma. 1970 Dec; 10(12): 1103-1108. Go to original source...
    2. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev. 2006 Apr; 19(2): 403-434. Go to original source... Go to PubMed...
    3. Belba MK, Petrela EY, Belba AG. Epidemiology and outcome analysis of sepsis and organ dysfunction/failure after burns. Burns. 2017 Sep; 43(6): 1335-1347. doi: 10.1016/j.burns.2017. 02. 017. Go to original source... Go to PubMed...
    4. Steed DL. Debridement. Am J Surg. 2004 May; 187(5 A): 71S-74S. Go to original source... Go to PubMed...
    5. Herndon DN. Total burn care. Enzymatic debridement of burn wounds. Elsevier Health Sciences, 2017.
    6. Krieger Y, Rosenberg L, Lapid O, Glesinger R, Bogdanov-Berezovsky A, Silberstein E, Sagi A, Judkins K. Escharotomy using an enzymatic debridement agent for treating experimental burn-induced compartment syndrome in an animal model. J Trauma. 2005 Jun; 58(6): 1259-1264. Go to original source... Go to PubMed...
    7. Ramli ANM, Manas NHA, Hamid AAA, Hamid HA, Illias RM. Comparative structural analysis of fruit and stem bromelain from Ananas comosus. Food Chem. 2018 Nov 15; 266: 183-191. doi: 10.1016/j.foodchem.2018. 05. 125. Go to original source... Go to PubMed...
    8. Brömme D. Papain-like cysteine proteases. Curr Protoc Protein Sci. 2001 May; Chapter 21: Unit 21. 2. Go to original source... Go to PubMed...
    9. Hale LP, Greer PK, Trinh CT, James CL. Proteinase activity and stability of natural bromelain preparations. Int Immunopharmacol. 2005 Apr; 5(4): 783-793. Go to original source... Go to PubMed...
    10. Pavan R, Jain S, Shraddha, Kumar A. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012; 2012: 976203. Go to original source... Go to PubMed...
    11. Ritonja A, Rowan AD, Buttle DJ, Rawlings ND, Turk V, Barrett AJ. Stem bromelain: amino acid sequence and implications for weak binding of cystatin. FEBS Lett. 1989 Apr 24; 247(2): 419-424. Go to original source... Go to PubMed...
    12. Klein GK. Enzymatic debridement of third degree burns in animals with bromelains. A preliminary report. J Maine Med Assoc. 1964 Sep; 55: 169-171. Go to PubMed...
    13. Houck JC, Chang CM, Klein G. Isolation of an effective debriding agent from the stems of pineapple plants. Int J Tissue React. 1983; 5(2): 125-134. Go to PubMed...
    14. Rosenberg L, Lapid O, Bogdanov-Berezovsky A, Glesinger R, Krieger Y, Silberstein E, Sagi A, Judkins K, Singer AJ. Safety and efficacy of a proteolytic enzyme for enzymatic burn debridement: a preliminary report. Burns. 2004 Dec; 30(8): 843-850. Go to original source... Go to PubMed...
    15. Rigueros Springford L, Creasy H, Cubison T, Dheans, B.A. novel technique of NexoBrid(TM) application to burns on the hands. Burns. 2017 Aug;43(5): 1132-1133. doi: 10.1016/j.burns.2017.02.013. Go to original source... Go to PubMed...
    16. Miller JM, Godfrey GC, Ginsberg M, Papastrat CJ. Clinical experience with panafil. Postgrad Med. 1957 Dec; 22(6): 609-613. Go to original source... Go to PubMed...
    17. Rutter PM, Carpenter B, Hill SS, Locke IC. Varidase: the science behind the medicament. J Wound Care. 2000 May; 9(5): 223-226. Go to original source... Go to PubMed...
    18. Dimick AR. Experience with the use of proteolytic enzyme (Travase) in burn patients. J Trauma. 1977 Dec; 17(12): 948-955. Go to original source... Go to PubMed...
    19. Shi L, Carson D. Collagenase Santyl ointment: a selective agent for wound debridement. J Wound Ostomy Continence Nurs. 2009 Nov-Dec; 36(6 Suppl): S12-S16. Go to original source... Go to PubMed...
    20. Smith F, Dryburgh N, Donaldson J, Mitchell M. Debridement for surgical wounds. Cochrane Database Syst Rev. 2011 May 11; (5): CD006214. Go to original source... Go to PubMed...
    21. Oh H, Boo S. Quality of life and mediating role of patient scar assessment in burn patients. Burns. 2017 Sep; 43(6): 1212-1217. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.